A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
Public ClinicalTrials.gov record NCT05730725. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
Study identification
- NCT ID
- NCT05730725
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 109 participants
Conditions and interventions
Conditions
Interventions
- BMS-986322 Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2, 2023
- Primary completion
- Aug 5, 2024
- Completion
- Aug 5, 2024
- Last update posted
- Nov 24, 2025
2023 – 2024
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0006 | Birmingham | Alabama | 35205-5021 | — |
| Local Institution - 0012 | Encino | California | 91436 | — |
| Local Institution - 0005 | Fountain Valley | California | 92708-3701 | — |
| Local Institution - 0002 | Fremont | California | 94538 | — |
| Local Institution - 0001 | Los Angeles | California | 90045-3606 | — |
| Local Institution - 0016 | Los Angeles | California | 90056 | — |
| Local Institution - 0003 | Santa Ana | California | 92701-2201 | — |
| Local Institution - 0013 | Coral Gables | Florida | 33134-5736 | — |
| Local Institution - 0056 | Skokie | Illinois | 60077-1049 | — |
| Local Institution - 0044 | Clarksville | Indiana | 47129-2201 | — |
| Local Institution - 0057 | Leawood | Kansas | 66211 | — |
| Local Institution - 0004 | Beverly | Massachusetts | 01915-1672 | — |
| Local Institution - 0060 | Lee's Summit | Missouri | 64064 | — |
| Local Institution - 0007 | Portsmouth | New Hampshire | 03801 | — |
| Local Institution - 0055 | Durham | North Carolina | 27713-8507 | — |
| Local Institution - 0008 | Cleveland | Ohio | 44106-1716 | — |
| Local Institution - 0058 | Rapid City | South Dakota | 57702-9208 | — |
| Local Institution - 0059 | Dallas | Texas | 75230-5808 | — |
| Local Institution - 0011 | Webster | Texas | 77598 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05730725, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 24, 2025 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05730725 live on ClinicalTrials.gov.